156 related articles for article (PubMed ID: 23706986)
1. NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Pinilla-Dominguez P; Richardson J; Robertson J; Adam J
Lancet Oncol; 2013 Jul; 14(8):691-2. PubMed ID: 23706986
[No Abstract] [Full Text] [Related]
2. NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.
Dyer M; Richardson J; Robertson J; Adam J
Lancet Oncol; 2013 Jul; 14(8):689-90. PubMed ID: 23706983
[No Abstract] [Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
[TBL] [Abstract][Full Text] [Related]
6. Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Dohrmann T; Kutup A; Mahner S; Müller V; Jaenicke F; Izbicki JR; Vashist YK
J Clin Oncol; 2013 Apr; 31(12):e208-10. PubMed ID: 23509305
[No Abstract] [Full Text] [Related]
7. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract][Full Text] [Related]
8. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
10. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Havrilesky LJ; Secord AA; Kulasingam S; Myers E
Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
[TBL] [Abstract][Full Text] [Related]
11. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
12. A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Wu MD; Wang Y; Ding T; Zhou YF; Song J; Liu XH; Wei MH; Yang QH; Zhou J; Wang SH; Lv QY
Indian J Cancer; 2014 Mar; 51 Suppl 3():e103-5. PubMed ID: 25818733
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF; Meydanli MM; Tulunay G
Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
[TBL] [Abstract][Full Text] [Related]
14. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
17. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang Y; Husain A; Blank S
Gynecol Oncol; 2014 Apr; 133(1):105-10. PubMed ID: 24508841
[TBL] [Abstract][Full Text] [Related]
18. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
[TBL] [Abstract][Full Text] [Related]
20. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Richardson DL; Backes FJ; Seamon LG; Zanagnolo V; O'Malley DM; Cohn DE; Fowler JM; Copeland LJ
Gynecol Oncol; 2008 Dec; 111(3):461-6. PubMed ID: 18829088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
